The trial enrolled 340 patients and assessed Vanrafia’s safety, tolerability, and efficacy over 132 weeks.

Novartis AG (NYSE:NVS) is one of the best cheap stocks to buy for beginners. Novartis AG (NYSE:NVS) announced on June 3 new ...

By Bhanvi Satija May 31 (Reuters) - Novartis said on Sunday that early data from its experimental actinium-based drug showed ...

Novartis' phase III report on Vanrafia shows slower kidney function decline in IgAN patients: Basel, Switzerland Saturday, June 6, 2026, 14:00 Hrs [IST] Swiss pharma major Novarti ...

Novartis (SWX:NOVN) reported that its drug Cosentyx achieved significant Phase III results in the REPLENISH trial for ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal with ...

CNW/ - Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") is pleased to announce the successful conclusion of ...

Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year guidance. Net sales were up 15% on a constant currency basis to $13.2 billion, ...

Novartis will cut 76 jobs at its East Hanover headquarters as the drugmaker continues a global restructuring effort.

A woman journeys through inherited memories and family history to uncover the hidden impact of cardiovascular disease in a ...

The New Jersey layoffs by Barclays, JPMorgan Chase, Meta and Novartis come as firms deal with the impact of inflation, economic uncertainty, and AI.

In a report released today, James Vane from Jefferies maintained a Hold rating on Novartis AG, with a price target of CHF110.00. According to TipRanks, Vane is ranked #10593 out of 12227 analysts.